--- title: "Aprea Therapeutics | 8-K: FY2026 Q1 Revenue Meets Estimate at USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286243356.md" datetime: "2026-05-13T10:37:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286243356.md) - [en](https://longbridge.com/en/news/286243356.md) - [zh-HK](https://longbridge.com/zh-HK/news/286243356.md) --- # Aprea Therapeutics | 8-K: FY2026 Q1 Revenue Meets Estimate at USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0, meeting the estimate of USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.22, beating the estimate of USD -0.23. EBIT: As of FY2026 Q1, the actual value is USD -3.565 M. #### Cash and Cash Equivalents Aprea Therapeutics, Inc. reported cash and cash equivalents of $46.5 million as of March 31, 2026, an increase from $14.6 million as of December 31, 2025 . The company had approximately $46.5 million in cash and equivalents as of March 31, 2026 . #### Operating Loss For the first quarter ended March 31, 2026, Aprea Therapeutics, Inc. reported an operating loss of - $3.4 million, which improved from an operating loss of - $4.1 million in the first quarter of 2025 . #### Research and Development (R&D) Expenses R&D expenses for the first quarter ended March 31, 2026, were $1.6 million, down from $2.5 million for the comparable period in 2025 . This decrease was primarily due to a - $0.8 million reduction related to the ABOYA-119 clinical trial . #### General and Administrative (G&A) Expenses G&A expenses remained consistent at $1.8 million for both the first quarter of 2026 and 2025 . #### Net Loss The net loss for the first quarter ended March 31, 2026, was - $3.3 million, an improvement compared to a net loss of - $3.9 million for the same period in 2025 . #### Net Loss Per Share Net loss per basic share was - $0.22 for the first quarter of 2026, compared to - $0.66 per basic share in the first quarter of 2025 . #### Grant Revenue Grant revenue was $0 for the first quarter of 2026, down from $162,463 in the first quarter of 2025 . #### Other Income Interest income, net, was $134,784 for Q1 2026, compared to $204,726 for Q1 2025 . Foreign currency gain was $7,711 for Q1 2026, shifting from a loss of - $51,803 in Q1 2025 . #### Gross Proceeds from Private Placement Aprea Therapeutics, Inc. closed an oversubscribed $30 million private placement on March 31, 2026, with proceeds intended to support the development of APR-1051 and general corporate purposes . Aprea Therapeutics, Inc. raised $30.0 million in gross proceeds from a private placement that closed on March 31, 2026 . #### Operational Highlights The ACESOT-1051 trial of WEE1 inhibitor APR-1051 observed two partial responses, with one confirmed at a second imaging assessment . Dose escalation is ongoing in the 300 mg cohort for ACESOT-1051, with plans to expand enrollment to include at least 50 patients with uterine serous carcinoma and cyclin E-overexpressing, platinum-resistant ovarian cancer . The ABOYA-119 clinical trial for ATRN-119 was strategically paused for monotherapy, and the company is exploring combination approaches and potential investigator-led studies . In February 2026, Dr. Eugene Kennedy was appointed as Chief Medical Advisor . #### Securities Common Equivalents (as of May 13, 2026) Preferred Stock (as converted) totaled 15,596, Common Stock was 12,382,776, Warrants amounted to 89,638,517, Options were 1,050,501, and Restricted Stock Units were 48,718 . The fully diluted equivalents totaled 103,120,512 . #### Outlook / Guidance Aprea Therapeutics, Inc. anticipates that its cash and cash equivalents of $46.5 million as of March 31, 2026, will be sufficient to meet projected operating expenses and capital expenditure requirements into the first quarter of 2028 . Additional clinical data from ACESOT-1051 is expected to be presented at the ASCO 2026 Annual Meeting on May 30, 2026, with completion of dose escalation anticipated in the second quarter of 2027 . For ATRN-119, the recommended Phase 2 dose (RP2D) was determined in October 2025, and potential collaborations on combinations are expected in the second half of 2026 . ### Related Stocks - [APRE.US](https://longbridge.com/en/quote/APRE.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate | ONNVF Stock News](https://longbridge.com/en/news/286620198.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)